Company intelligence / Profile preview
Nimbus Therapeutics
Boston/Cambridge area, Massachusetts, United Statesnimbustx.com ↗
- Ownership
- Private
- Employees
- ~125
- Development stage
- Other
01
Overview
Nimbus Therapeutics has advanced three programs into the clinic using its proprietary computational chemistry-driven approach. Its lead clinical asset includes an HPK1 inhibitor for cancer. The company previously achieved a major exit by selling its ACC program to Gilead. It continues to develop a diverse pipeline targeting oncology, immunology/autoimmunity, and metabolic diseases with highly selective small molecules.
- Therapeutic areas
- OncologyImmunologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Takeda Pharmaceuticals – partnered on autoimmune drug development including psoriasis therapy.Gilead Sciences – acquired the ACC inhibitor subsidiary/program from Nimbus in a landmark deal ($400M upfront + milestones).
Beyond the preview
Go deeper on Nimbus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nimbus Therapeutics.